The foremost gathering of CEOs of international and local pharmaceutical producers, distributors and retailers

14 - 15 May 2019

Corinthia Saint-Petersburg Hotel

First speaker confirmations in 2019

Elizabeth is currently the Real World Evidence generation Leader for China and Emerging Markets at Sanofi, Paris France.

Elizabeth is a Rheumatologist and Epidemiologist, with 18 years of experience in Real World Evidence and Market Access, spanning across research, consulting and Pharma.
Elizabeth has worked with regulators, payers, health care providers, and patients, to support decision-making through state of the art evidence, and more recently is part of the digital transformation, leveraging the most state of the art digital tools and ways of working to raise the level of innovation in evidence generation to improve patient outcomes.
Elizabeth is a Rheumatologist and an Epidemiologist, with an MPH from Harvard University.

Alex Zhavoronkov, PhD
Expert in AI for healthcare and longevity biotechnology
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (, a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning for generating the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He was the first to develop deep multi-modal predictors of age using multiple data types. He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple digital biomarker initiatives including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, and YLabs.AI and established competitions and Diversity.AI initiative. He is the co-founder and chief science officer (CSO) of the Biogerontology Research Foundation (BGRF,, a registered UK charity focusing on age-related diseases. Since 2012 he published over 130 peer-reviewed research papers and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). From 2014 to 2018 he presented at over 200 academic and industry conferences. He serves on the editorial boards of some of the highest-impact journals in the field including Aging, Aging Research Reviews, Frontiers in Genetics of Aging, and chairs the Annual Aging Research for Drug Discovery Forum (5th annual in 2018) and the Artificial Intelligence for Healthcare Forum (2nd annual) at the Basel Life, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Graduated from the Geography Department of Kazan Federal University. Received an MBA at the Management School of Lancaster University (UK). Has over 20 years of experience in senior managerial positions in the pharmaceutical industry.

In 2011 won the “Manager of the Year” as per Platinum Ounce award, a prominent professional award in the Russian pharmaceutical field. In 2015, became the Head of the Eurasia business unit — encompassing Russia, the CIS states, Georgia and the Ukraine — in a pharmaceutical company Bosnalijek (Bosnia and Herzegovina), one of the largest pharmaceutical manufacturers in the Balkan States and Eastern Europe. Recently, the business unit led by Valentina has increased its influence by entering the markets of Kazakhstan, Belarus and Azerbaijan.

In 2017, Bosnalijek, with its production sites in Sarajevo, became one of the first companies that had its application approved by the Russian Ministry of Industry and Trade and received a GMP certificate. The Russian market is vital to Bosnalijek’s future; it is the second year in a row that Bosnalijek sales continue to grow at a double-digit rate, which is significantly faster than the market. Bosnalijek best sellers are LYSOBACT and ENTEROFURYL, ranking among Top 3 in their categories.

Dr. Mikhail Samsonov is currently Head of Development, Medical and Regulatory at  R-Pharm managing all activities across several therapeutic areas (cardiology, oncology, infectious and autoimmune disease)  in fast growing R&D company. He is a member of several Joint Steering Committees with Merck, Eli Lilly, UCB, Theravance, Quintiles etc dedicated to technology transfer, development and commercialisation of innovative medicines, biosimilars and generics .

Prior R-Pharm he was Chief Scientific Officer at Novartis Russia & CIS overseeing all R&D activities for Novartis in one of key complex emerging markets and  member of Board of Directors Association of Clinical Trials Organizations in Russia in 2009-2011.

Dr Samsonov was Executive Director Regional Clinical Operations at Bristol-Myers Squibb Company overseeing EMEA and Asia Pacific regions including such emerging markets as China, India and Eastern Europe during last three years in BMS.  With over 14 years of experience at BMS in variety of roles in medical affairs and clinical operations, Dr Samsonov has dedicated much of his career to building capabilities in fast-growing clinical research markets , continuous productivity improvement in well established R&D markets and developing  10 new molecules in several areas ( antibiotics, autoimmune, CNS, CVS, oncology, virology). He was based at several BMS offices in the US, UK, Russia and Belgium.

Dr. Samsonov’s education includes MD from Moscow Medical University, National Cardiology Centre (Moscow) training  in Clinical Cardiology,  Ph.D. in Cardiology & Immunology from National Cardiology Centre, BA from Open University, London and several  business courses at INSEAD and OWEN business school.

He is an active speaker and panel expert at Columbia Business School, NY and various international conferences DIA, BIO USA, industry and investor meetings  on development  strategies, operational models, vendor management  in established and  emerging markets.  

In 1988 graduated from the Chelyabinsk State Medical Institute with a specialization in «General Medicine».
In 1998 completed postgraduate studies and defended a thesis on «anesthesiology-resuscitation» and «oncology» in the P.A. Herzen Moscow Oncology Research Institute.
Worked as a practitioner in various medical institutions of the RF, held senior positions in the Ministry of Health of the RF, in the Ministry of Health of Moscow Region and in leading pharmaceutical companies: MEDSI Group of Companies, Pharmeco LLC, Biotec LLC.
Since April 2018 has taken up the position of CEO of PJSC «Pharmacy Chain 36.6»
In 2002 and 2006 the Ministry of Health of Moscow Region gave Mr. Nesterenko a commendation for his diligent work.